Briffod M, Spyratos F, Tubiana-Hulin M, Pallud C, Mayras C, Filleul A, Rouëssé J
Centre René Huguenin de Lutte contre le Cancer, Saint-Cloud, France.
Cancer. 1989 Feb 15;63(4):631-7. doi: 10.1002/1097-0142(19890215)63:4<631::aid-cncr2820630405>3.0.co;2-w.
Thirty-five patients with large but operable breast carcinoma (T3, N0-N1, M0) received before surgery three cycles of preoperative Adriamycin (doxorubicin), vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (AVCMF) chemotherapy (CT). All patients had sequential cytopunctures for both cytologic examination and flow cytometric DNA analysis (FCM): one before treatment and the three others after each cycle of CT. At cytologic examination, 20 carcinomas showed CT-induced cytomorphologic changes. These changes in malignant cells were also evaluated on histologic sections after surgery. A significant relationship was found between cytomorphologic changes in cytopunctures and in the corresponding tumor tissue. The lobular carcinomas did not reveal changes either on cytologic or on histologic study. At FCM analysis before treatment, ten carcinomas were diploid and 25 were nondiploid. When initial tumor ploidy was compared to cytomorphologic changes, none of the diploid carcinomas showed changes. An objective tumor regression was observed in 12 of 20 tumors with cytomorphologic changes and in four of 15 tumors without changes on cytologic examination. But, a significant relationship appeared only when cellular changes were evaluated on histologic analysis. When tumor regression was compared to ploidy before treatment, the rate of objective regression was significantly higher in nondiploid tumors (15/25) than in diploid tumors (one of ten). From these findings, initial tumor diploidy could be a predictor of tumor chemoresistance, whereas cytomorphologic changes during chemotherapy could be an indicator of tumor cell chemosensitivity.
35例患有体积较大但可手术切除的乳腺癌(T3,N0 - N1,M0)患者在手术前接受了三个周期的术前阿霉素(多柔比星)、长春新碱、环磷酰胺、甲氨蝶呤、5 - 氟尿嘧啶(AVCMF)化疗(CT)。所有患者均进行了序贯细胞穿刺,用于细胞学检查和流式细胞术DNA分析(FCM):治疗前一次,CT的每个周期后各一次。在细胞学检查中,20例癌显示出CT诱导的细胞形态学变化。手术后在组织学切片上也对恶性细胞的这些变化进行了评估。发现细胞穿刺和相应肿瘤组织中的细胞形态学变化之间存在显著关系。小叶癌在细胞学或组织学研究中均未显示变化。在治疗前的FCM分析中,10例癌为二倍体,25例为非二倍体。当将初始肿瘤倍性与细胞形态学变化进行比较时,所有二倍体癌均未显示变化。在20例有细胞形态学变化的肿瘤中有12例观察到客观肿瘤退缩,在15例细胞学检查无变化的肿瘤中有4例观察到客观肿瘤退缩。但是,仅在组织学分析中评估细胞变化时才出现显著关系。当将肿瘤退缩与治疗前的倍性进行比较时,非二倍体肿瘤(15/25)的客观退缩率明显高于二倍体肿瘤(10例中的1例)。从这些发现来看,初始肿瘤二倍体可能是肿瘤化疗耐药性的预测指标,而化疗期间的细胞形态学变化可能是肿瘤细胞化疗敏感性的指标。